Jacobs Levy Equity Management’s aTyr Pharma ATYR Stock Holding History

Jacobs Levy Equity Management’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,029	Closed	-$75K	–	1116
2018 Q1	$75K	Sell	2,029 -607	-23%	-$28.4K	﹤0.01%	974
2017 Q4	$129K	Sell	2,636 -758	-22%	-$46.6K	﹤0.01%	943
2017 Q3	$240K	Buy	+3,394	New	+$157K	﹤0.01%	827
2017 Q1	–	Sell	-6,791	Closed	-$204K	–	1010
2016 Q4	$204K	Sell	6,791 -3,135	-32%	-$129K	﹤0.01%	831
2016 Q3	$442K	Buy	9,926 +6,330	+176%	+$274K	0.01%	740
2016 Q2	$140K	Buy	3,596 +596	+20%	+$27.7K	﹤0.01%	1060
2016 Q1	$165K	Buy	+3,000	New	+$228K	﹤0.01%	993

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GHCM

Glen Harbor Capital Management San Diego, California $4.82B AUM 4.69% 1-Year Est. Return

Jacobs Levy Equity Management's ATYR Position: Q2 2018 in Review

Jacobs Levy Equity Management sold out of aTyr Pharma (ATYR) in Q2 2018, closing a stake of 2,029 shares — an estimated $75K sold.

Jacobs Levy Equity Management first reported a position in ATYR in Q1 2016 and held it in 7 quarters. The position peaked at $442K in Q3 2016. 33 funds tracked by Wall St. Rank hold ATYR as of Q2 2018.

Jacobs Levy Equity Management reported no remaining aTyr Pharma position as of Q2 2018 after selling out during the quarter.
Jacobs Levy Equity Management sold 2,029 aTyr Pharma shares in Q2 2018, an estimated $75K.
Jacobs Levy Equity Management first reported a position in aTyr Pharma in Q1 2016 and held it in 7 quarters.
Jacobs Levy Equity Management's aTyr Pharma position peaked at $442K in Q3 2016.
33 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2018, filed 14 Aug 2018.